Longevity Biotech, Timeline, Leads the Way in Healthy Aging Research with Groundbreaking Clinical Studies
06 Mayo 2024 - 7:38AM
Business Wire
Mitopure Slows Immune System Aging by Re-energizing T-Cells
for Enhanced Protection
Regulatory News:
Timeline®, a pioneering Swiss consumer biotech company at the
forefront of longevity research, is proud to announce the
successful completion of its landmark immune aging clinical study,
MitoImmune, using Mitopure (proprietary Urolithin A). Additionally,
the company has partnered on two new clinical trials in
collaboration with prestigious research institutions to expand its
applications of Mitopure for healthy aging. Timeline, backed by
Nestlé and L'Oréal Group investments, builds on 15 years of
research and multiple clinical studies.
"Our mission has always been to pioneer research that unlocks
clinically proven interventions to help people stay healthier for
longer. These results open a totally new approach to directly
impact our immune cells and help restore their functionality during
aging." - Chris Rinsch, PhD, Co-Founder and President of
Timeline.
"This is groundbreaking research that helps us better understand
how we can counter the age-related decline of our immune system and
shows us that we can rewire our bodies defense with targeted
mitochondrial interventions like Mitopure." - Dr. Eric Verdin, CEO
and President of the Buck Institute for Research on Aging.
"Our collaboration with Timeline on the MitoImmune study has
provided invaluable insights into the intersection of mitochondrial
health and immune function. These findings may prove important for
the oncology community." - Dr. Dominic Denk, MD, Principal
Investigator of MitoImmune Study.
The MitoImmune study is an unprecedented intervention-based
assessment of immune aging. This randomized, placebo-controlled
study was conducted in collaboration with the Georg-Speyer-Haus
Institute for Tumor and Experimental Therapy and the Buck Institute
of Aging in California, USA. The study enrolled 50 middle-aged
adults over a four-week intervention with Mitopure. T-cells, key
for fighting infections and age-related diseases, decline
dramatically in both number and quality with age. The key study
co-primary endpoints were an increase of the youthful naive CD8
T-cells, and an improvement in mitochondrial activity of these
T-cells. Both the study primary endpoints were successfully met
with Mitopure intervention compared to placebo. Other key secondary
endpoints including reduction of inflammaging were also met. The
topline results from the study were presented on May 5, 2024 at the
leading immunology conference, American Association of
Immunologists (AAI), in Chicago.
Building on the success of the research on Mitopure to date, the
company is pleased to support two additional investigator-led
clinical trials with esteemed partners:
In collaboration with the National Institute of Aging, we're
investigating the impact of Mitopure on glucose metabolism in
middle-aged overweight adults. This study aims to uncover the
potential of Mitopure to improve metabolic health and mitigate
age-related metabolic decline.
Timeline is also collaborating with the National Institute of
Cancer that is evaluating the impact of Mitopure on oxidative
stress in adults diagnosed with prostate cancer. This new study
seeks to uncover the potential of Mitopure in managing oxidative
stress and its implications for cancer patients. For more
information about Timeline and our ongoing research initiatives,
please visit www.timeline.com/studies
About Timeline Timeline (parent company Amazentis) is a
pioneering Swiss health science company committed to
revolutionizing the longevity industry with its groundbreaking,
clinically proven, proprietary ingredient Mitopure®. Offering a
comprehensive approach to cellular health, Timeline incorporates
the benefits of Mitopure inside its next generation nutritional
supplements and topical skin health products. With more than a
decade of expertise in aging science research, Timeline seeks to
push the boundaries of human healthspan, contributing to a future
where everyone can live longer, healthier lives. The company is
backed by over 15 years of research by distinguished scientists,
multiple clinical studies, and over 50 global patents. Nestlé
Health Science and L’Oréal are investors in the company.
www.timeline.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506548618/en/
Press Contact: Federico Luna. Chief Marketing Officer,
Timeline: fluna@timeline.com